# Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's disease

> **NIH NIH RF1** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $171,239

## Abstract

PROJECT SUMMARY
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with severe impairment of memory,
cognition and executive functions that has a tremendous health and economic burden. Neurovascular unit (NVU)
and blood-brain barrier (BBB) dysfunction play a key etiological role in AD progression; yet the contribution of
genetic versus environmental risk factors for brain microvascular damage is unclear. This project will generate
validated human pluripotent stem cells (PSC)-derived NVU cells, develop a perfused microphysiological NVU
3D system with plasma or blood from young or aged patients and compare its transcriptome profiles with the
human AD brain vasculome to dissect the contribution of genetic versus age-related factors in AD. We have
used CRISPR/Cas9 methodology to knock-in FAD or LOAD mutations in control PSC cell lines, and developed
strategies to differentiate PSC-derived cells into brain microvascular endothelial cells (BMECs), pericytes or
astrocytes and build brain-on-a-chip models with NVU cells and flow. Moreover, our preliminary single nucleus
RNA-seq of human AD brains has identified 4 distinct BMEC populations, at the transcriptome level, one of which
is positively correlated with cognitive impairment, A and tau accumulation. We hypothesize that synergistic
interactions between genetic and environmental risk factors impair NVU function and BBB properties by altering
key neurovascular signaling pathways or transcription factors. We will address this hypothesis with three aims.
In Aim 1, we will optimize protocols to generate BMECs via transdifferentiation from primed ECs, verify their
molecular identity with single cell RNA-seq and validate their biological function using relevant cellular, imaging
and functional approaches. We will incorporate BMECs into an NVU microfluidic system along with hPSC-
derived pericytes and astrocytes and compare cell biological, transcriptome, imaging and functional barrier
properties between NVUs carrying AD-associated risk genes and isogenic controls. In Aim 2, we will isolate the
vasculome compartment from human post-mortem brains and assess differences in vasculome profiles from
control and AD brains. We will evaluate whether AD-associated transcriptional changes in BMECs, pericytes
and astrocytes in vivo are present in the microphysiological NVU 3D system derived from hPSC lines carrying
AD-associated risk genes. Finally in Aim 3, we will assess whether treatment with proteasome inhibitors (to
mimic loss of proteostatis), agents that produce advanced glycation end products, or dynamic flow of aged versus
young blood from control or AD patients alters the morphology and transcriptome profiles of NVU cells and
transport across the BBB. This Diversity Supplement will allow us to extend these studies to characterize LOAD
mutant astrocytes more deeply as well as see how induction of senescence modulates these phenotypes both
in monolayer and in 3D NVUs. The proposed studies wil...

## Key facts

- **NIH application ID:** 10915139
- **Project number:** 3RF1AG078352-01S1
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** Dritan Agalliu
- **Activity code:** RF1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $171,239
- **Award type:** 3
- **Project period:** 2022-09-30 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10915139

## Citation

> US National Institutes of Health, RePORTER application 10915139, Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's disease (3RF1AG078352-01S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10915139. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
